Glioblastoma: Bevacizumab may have failed but imaging techniques may just cure cancer, according to research.

Glioblastoma multiforme is the most common form of brain cancer wherein diagnosed patients usually survive a life expectancy of just less than two years.

There has been an ongoing study about the possible cure for Glioblastoma. However, recent reports claim that the study, which is the randomized trial of Bevacizumab, have shows disappointing results.

The randomized Bevacizumab trial is a controlled trial which used double-blind placebo on 621 adults. It was funded for by the National Cancer Institute and drug manufacturer Genentech from 2009 to2012.

Dr. Brachman, the Director of Radiation Oncology at Barrow and St. Joseph's Hospital and Medical Center says, "The results of this study are counter to most expectations." He adds, "Bevacizuman had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival."

As bleak as this news may sound for Glioblastoma multiforme's cure, world-leading instrumentation company called Bruker claims that preclinical imaging techniques maximized may link cancer diagnosis and treatment.

Bruker claims that imaging techniques are essential to the effective testing of cancer treatments. Insights asserted by the company are based on research of renowned scientists using animal models for treatment testing.

According to Bruker, understanding both requirements and benefits of utilizing an MRI (Magnetic Resonance Imaging) machine for glioblastoma multiforme and other types of cancer can help in the prevention and cure of the disease.

If used accordingly, MRI, and other forms of imaging technologies may just provide quick, accurate and detailed answers to answer treatment questions posed by many.

Glioblastoma may not be so hopeless after all. Bevacizumab may have failed, but these modern imaging techniques may pave the way to a better cancer-free future.